VRTX

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.

Vertex Pharmaceuticals Incorporated (VRTX) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Growth (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
C+
Factor Score 2.6 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
B+
Factor Score 3.7 / 5.0
Momentum
B
Factor Score 3.4 / 5.0
Revisions
C+
Factor Score 2.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 34.7
EV / EBITDA 26.8
Rev Growth YoY 11.8%
Gross Margin 54.8%
Price Return 3M 4.5%
Price Return 12M 24.1%
Catalyst Signal +0.17
Market Cap $136.6B
TTM Revenue $13.0B
Price / Sales 10.5
ROE 20.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 C+ (2.6) C- (1.9) B+ (3.7) B (3.4) C+ (2.5) C+ (2.8)
2026-11-09 C (2.5) C- (1.9) B+ (3.6) B (3.4) C+ (2.5) C+ (2.8)
2026-11-04 C+ (2.6) C- (2.1) B+ (3.7) B+ (3.6) C+ (2.6) B- (2.9)
2026-11-03 C+ (2.6) C- (2.1) B+ (3.7) B (3.4) C (2.5) B- (2.9)
2026-11-02 C+ (2.6) C- (2.1) B+ (3.7) B (3.4) C (2.2) C+ (2.8)
Page 1 of 6